aTyr Pharma Inc
ATYR
Company Profile
Business description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Contact
10240 Sorrento Valley Road
Suite 300
San DiegoCA92121
USAT: +1 858 731-8389
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.60 | 49.30 | -0.55% |
| CAC 40 | 8,106.16 | 0.00 | 0.00% |
| DAX 40 | 24,076.87 | 153.04 | -0.63% |
| Dow JONES (US) | 48,114.26 | 302.30 | -0.62% |
| FTSE 100 | 9,684.79 | 66.52 | -0.68% |
| HKSE | 25,235.41 | 393.47 | -1.54% |
| NASDAQ | 23,111.46 | 54.05 | 0.23% |
| Nikkei 225 | 49,383.29 | 784.82 | -1.56% |
| NZX 50 Index | 13,371.94 | 53.01 | -0.39% |
| S&P 500 | 6,800.26 | 16.25 | -0.24% |
| S&P/ASX 200 | 8,598.90 | 48.40 | -0.56% |
| SSE Composite Index | 3,824.81 | 43.11 | -1.11% |